Literature DB >> 25144163

Survival outcomes in advanced laryngeal cancer.

Uchechukwu C Megwalu1, Andrew G Sikora1.   

Abstract

IMPORTANCE: Chemoradiation therapy has become increasingly popular in the treatment of advanced laryngeal cancer as part of an organ preservation protocol. However, several studies have reported a decline in survival, possibly attributable to the increased use of radiation and chemoradiation therapy.
OBJECTIVE: To evaluate survival outcomes of laryngeal conservation vs surgical therapy in the treatment of advanced laryngeal cancer in the United States using a large population-based cancer database. DESIGN, SETTING, AND PARTICIPANTS: Population-based, nonconcurrent cohort study of 5394 patients who received a diagnosis of stage III or IV laryngeal squamous cell carcinoma between 1992 and 2009. Data were extracted from the Surveillance, Epidemiology, and End Results 18 Database.
INTERVENTIONS: Surgical or nonsurgical therapy. MAIN OUTCOMES AND MEASURES: Overall survival (OS) and disease-specific survival (DSS).
RESULTS: Patients who received surgical therapy had better 2-year and 5-year DSS (70% vs 64% and 55% vs 51%, respectively; P < .001) and 2-year and 5-year OS (64% vs 57% and 44% vs 39%, respectively; P < .001) than patients who received nonsurgical therapy. The difference in DSS and OS between treatment groups remained after stratification by year-of-diagnosis cohorts (P < .001). The survival gap consistently narrowed with subsequent year-of-diagnosis cohorts. On multivariable analysis, nonsurgical patients had worse DSS (hazard ratio [HR], 1.33 [95% CI, 1.21-1.45]) and OS (HR, 1.32 [95% CI, 1.22-1.43]) after adjustment for year of diagnosis, American Joint Committee on Cancer stage, age, sex, subsite, race, and marital status. Stage III disease (HR, 0.59 [95% CI, 0.54-0.65]), glottic subsite (HR, 0.74 [95% CI, 0.67-0.82]), 2004 to 2009 year-of-diagnosis cohort (HR, 0.79 [95% CI, 0.70-0.90]), female sex (HR, 0.80 [95% CI, 0.72-0.89]), and married status (HR, 0.68 [95% CI, 0.62-0.75]) positively affected DSS. Black race (HR, 1.17 [95% CI, 1.05-1.30]) and increased age (HR, 1.03 [95% CI, 1.02-1.03] for each year) negatively affected DSS. CONCLUSIONS AND RELEVANCE: Surgical therapy leads to better survival outcomes than nonsurgical therapy for patients with advanced laryngeal cancer. Patients need to be made aware of the modest but significant survival disadvantage associated with nonsurgical therapy as part of the shared decision-making process during treatment selection.

Entities:  

Mesh:

Year:  2014        PMID: 25144163     DOI: 10.1001/jamaoto.2014.1671

Source DB:  PubMed          Journal:  JAMA Otolaryngol Head Neck Surg        ISSN: 2168-6181            Impact factor:   6.223


  44 in total

1.  Survival Rates Using Individualized Bioselection Treatment Methods in Patients With Advanced Laryngeal Cancer.

Authors:  Gregory T Wolf; Emily Bellile; Avraham Eisbruch; Susan Urba; Carol R Bradford; Lisa Peterson; Mark E Prince; Theodoros N Teknos; Douglas B Chepeha; Norman D Hogikyan; Scott A McLean; Jeffery Moyer; Jeremy M G Taylor; Francis P Worden
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2017-04-01       Impact factor: 6.223

Review 2.  Organ Preservation Protocols in T4 Laryngeal Cancer: a Review of the Literature.

Authors:  Narayana Subramaniam; Deepak Balasubramanian; Rithvik Reddy; Krishnakumar Thankappan; Subramania Iyer
Journal:  Indian J Surg Oncol       Date:  2018-12-01

3.  Understanding Risk Factors Associated With Unplanned Reoperation in Major Head and Neck Surgery.

Authors:  Neel R Sangal; Kalin Nishimori; Eric Zhao; Sana H Siddiqui; Soly Baredes; Richard Chan Woo Park
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2018-11-01       Impact factor: 6.223

4.  Characteristics and survival outcomes associated with the lack of radiation in the treatment of glioblastoma.

Authors:  Bin Huang; Therese A Dolecek; Quan Chen; Catherine R Garcia; Thomas Pittman; John L Villano
Journal:  Med Oncol       Date:  2018-04-17       Impact factor: 3.064

5.  Preoperative Tracheostomy Is Associated with Poor Disease-Free Survival in Recurrent Laryngeal Cancer.

Authors:  Andrew C Birkeland; Andrew J Rosko; Lauren Beesley; Emily Bellile; Steven B Chinn; Andrew G Shuman; Mark E Prince; Gregory T Wolf; Carol R Bradford; J Chad Brenner; Matthew E Spector
Journal:  Otolaryngol Head Neck Surg       Date:  2017-06-06       Impact factor: 3.497

6.  Locally advanced laryngeal cancer: Total laryngectomy or primary non-surgical treatment?

Authors:  Aleš Čoček; Miloslav Ambruš; Alena Dohnalová; Martin Chovanec; Martina Kubecová; Kateřina Licková
Journal:  Oncol Lett       Date:  2018-03-01       Impact factor: 2.967

7.  Predictive and prognostic factors for patients with locoregionally advanced laryngeal carcinoma treated with surgical multimodality protocol.

Authors:  Gorkem Eskiizmir; Gokce Tanyeri Toker; Onur Celik; Kivanc Gunhan; Ayca Tan; Hulya Ellidokuz
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-12-10       Impact factor: 2.503

8.  Long-term outcomes after multidisciplinary management of T3 laryngeal squamous cell carcinomas: Improved functional outcomes and survival with modern therapeutic approaches.

Authors:  Clifton D Fuller; Abdallah S R Mohamed; Adam S Garden; G Brandon Gunn; Collin F Mulcahy; Mark Zafereo; Jack Phan; Stephen Y Lai; Jan S Lewin; Katherine A Hutcheson; Steven J Frank; Beth M Beadle; William H Morrison; Adel K El-Naggar; Esengul Kocak-Uzel; Lawrence E Ginsberg; Merril S Kies; Randal S Weber; David I Rosenthal
Journal:  Head Neck       Date:  2016-07-28       Impact factor: 3.147

9.  CDR1as is overexpressed in laryngeal squamous cell carcinoma to promote the tumour's progression via miR-7 signals.

Authors:  Jianzhong Zhang; Huayong Hu; Yaoxin Zhao; Yulin Zhao
Journal:  Cell Prolif       Date:  2018-09-04       Impact factor: 6.831

10.  Predictors of survival after total laryngectomy for recurrent/persistent laryngeal squamous cell carcinoma.

Authors:  Andrew C Birkeland; Lauren Beesley; Emily Bellile; Andrew J Rosko; Rebecca Hoesli; Steven B Chinn; Andrew G Shuman; Mark E Prince; Gregory T Wolf; Carol R Bradford; J Chad Brenner; Matthew E Spector
Journal:  Head Neck       Date:  2017-09-30       Impact factor: 3.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.